Obesity engine facing tighter pricing and heavy concentration risk
- Mounjaro and Zepbound combined for more than $16 billion of revenue in Q3 2026.
- Management raised full year 2026 revenue guidance to between $91 billion and $92 billion.
- Underlying U.S. prices fell 10 percent in Q3 2026, showing a volume versus price trade off.
- The Inflation Reduction Act selected Trulicity and Verzenio for government set prices starting in 2028.
- New pipeline data showed retatrutide doubled the weight loss of older competitors in Phase 3 trials.
A weight loss leader with one main engine
Lilly is one of the main global suppliers of incretin medicines, a drug class used for type 2 diabetes and obesity. Mounjaro and Zepbound are the core products, combining for more than $16 billion of revenue in Q3 2026 and driving a 39 percent jump in total company sales. International demand is also growing fast, with Mounjaro becoming the first medicine in China to exceed $1 billion in revenue during its first full year.
The bull case grew stronger after Q3 2026. Management raised full year revenue guidance to a range of $91 billion to $92 billion. The Medicare GLP 1 Bridge program is expanding the market by bringing in mostly new patients. In the pipeline, retatrutide posted Phase 3 data showing it doubled the weight loss of older competitors, securing Lilly's lead in the next generation of injectables.
The bear case centers on pricing pressure and execution risk. The massive volume growth comes at a cost, as underlying U.S. pricing for these drugs declined 10 percent in Q3 2026. This pricing pressure is compounded by the Inflation Reduction Act, which selected older drugs like Trulicity for government set prices in 2028. The next year will come down to whether volume can outpace these price cuts and how the FDA views upcoming pipeline submissions targeted for 2027.
Patents, scale, and access deals
Lilly discovers, tests, makes, and sells branded prescription drugs. It spends heavily on research and development, then runs clinical trials to prove a drug works and is safe. If regulators approve the drug, patents give Lilly a period with limited generic competition. That is when the company can earn back the cost of research and make a profit.
Most revenue comes through sales to wholesalers, pharmacies, and healthcare providers around the world. The model now depends most on cardiometabolic drugs. Mounjaro treats type 2 diabetes. Zepbound treats obesity. Next generation drugs like oral Koundeo and injectable retatrutide are meant to expand the franchise. These drugs are driving massive volume growth, while lower realized prices are partly offsetting that growth.
Lilly also has other products that matter. Verzenio in cancer, Taltz in immunology, Jardiance in diabetes, Trulicity in diabetes, and Kisunla in Alzheimer's disease help broaden the business. LillyDirect adds a direct to consumer path by connecting patients with telehealth providers and home delivery for some medicines. Lilly Employer Connect is a newer platform for employers to offer obesity medicines.
The model can break in a few clear ways. Lilly must keep building enough manufacturing capacity for incretins without quality problems or delays. It must also accept lower prices in some channels to reach more patients. The core question is whether selling to many more patients at lower prices creates more profit than selling to fewer patients at higher prices.
The drugs that matter most
Mounjaro (tirzepatide, type 2 diabetes)
Mounjaro is Lilly's leading diabetes incretin and a main driver of recent revenue growth. Together with Zepbound, it combined for over $16 billion of sales in Q3 2026.
Zepbound (tirzepatide, obesity)
Zepbound is the obesity brand of tirzepatide. It is a major growth driver, but access can change fast because large payers can demand lower prices.
Foundayo / Koundeo (orforglipron, oral GLP 1)
Foundayo is Lilly's oral GLP 1 obesity drug. Early launch data showed most prescriptions were new to the class, supporting the market expansion case.
Retatrutide (triple agonist, obesity)
Retatrutide is an experimental injectable obesity drug that posted Phase 3 weight loss data doubling older competitor results. A U.S. filing is planned for early 2027.
Trulicity (dulaglutide, diabetes)
Trulicity is an older injectable GLP 1 for type 2 diabetes. It faces pricing pressure, volume declines, and will be subject to government set prices in 2028.
Verzenio (abemaciclib, oncology)
Verzenio is a cancer drug used mainly in breast cancer. It helps diversify Lilly but was also selected for government price setting in 2028.
Taltz (ixekizumab, immunology)
Taltz treats immune conditions such as psoriasis and psoriatic arthritis. It provides recurring revenue and adds balance to the portfolio.
Kisunla (donanemab, Alzheimer's disease)
Kisunla is approved for early symptomatic Alzheimer's disease. It gives Lilly a non obesity growth path, but adoption and reimbursement are still early.
One segment, one big concentration
Lilly reports one segment for human pharmaceutical products. The structured mix below separates the named Mounjaro and Zepbound concentration from the rest of the business, reflecting their dominance of total revenue as of early 2026.
What could break the Lilly thesis
Too much reliance on incretins
High impact · Medium oddsMounjaro and Zepbound continue to drive the vast majority of growth, combining for over $16 billion in Q3 2026 revenue. A safety issue, stronger competitor, or shift in doctor use for incretin drugs would hit most of Lilly's growth at once. Next generation drugs like retatrutide keep Lilly tied to the same broad class.
Payers take more price
High impact · High oddsLilly has agreements with the U.S. government to lower Medicaid and some other drug prices. The pressure is already showing, with underlying U.S. prices falling 10 percent in Q3 2026. The company must sell significantly more volume through new channels like the Medicare GLP 1 Bridge program to offset these cuts.
Government price setting
Medium impact · High oddsThe Inflation Reduction Act selected Trulicity and Verzenio for government set prices starting in 2028. Management expects other major products could be selected in future years, creating a long term headwind for older medicines and squeezing profit margins.
Manufacturing falls behind demand
High impact · Medium oddsLilly is carrying out large manufacturing expansion plans globally, including new sites in Indiana, Texas, Virginia, and Ireland, to meet demand for obesity and diabetes drugs. Any delay, quality issue, or capacity shortfall could lead to shortages, lost sales, or regulatory problems tied to manufacturing standards.
Competition and counterfeit incretins
Medium impact · Medium oddsDiabetes, obesity, and oncology are competitive markets. Rivals are developing injectable and oral obesity drugs that could lower Lilly's share or force lower prices. Lilly also warns about counterfeit, misbranded, adulterated, and compounded incretins, which can confuse patients and harm trust in the category.
In one breath
How does Eli Lilly make most of its money today?
Lilly makes most of its revenue from patented prescription drugs. Today the biggest drivers are Mounjaro and Zepbound, which treat type 2 diabetes and obesity and combined for over $16 billion in Q3 2026 sales.
What is Koundeo and why does it matter?
Koundeo, also called orforglipron or Foundayo, is Lilly's oral GLP 1 drug for obesity. It matters because it is easier to take than an injection and early data showed it is bringing new patients into the obesity market.
Why is pricing such a big issue for Lilly?
Lilly is gaining access to larger patient groups through government programs, but often at lower prices. In Q3 2026, underlying U.S. prices for its drugs fell 10 percent, meaning volume must grow fast enough to make up the difference.
Is Eli Lilly's stock price already assuming success?
Finn's valuation view is low, while growth and performance score much higher. That means the business is strong, but the market already expects huge profits from obesity drugs, Medicare access, and future pipeline wins.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- November 1, 2026
- Score data
- November 15, 2026
- Reviewed by
- Shivam Bharuka
Comparable Drug Manufacturers - General companies
Companies near Eli Lilly and Company in Finn's Drug Manufacturers - General industry ranking.

